Aurobindo Pharma announced that has received a warning letter dated 20 June 2019 from USFDA relating to its Unit XI, API manufacturing facility situated at Sy.No.61-66, IDA, Pydibhimavaram, Ranasthalam (Mandal), Srikakulam District, Andhra Pradesh.
This action follows the earlier inspection of the site by the USFDA Agency in February 2019. The company believes the existing business from this facility will not be impacted. The company will be engaging with the regulator and are fully committed in resolving this issue at the earliest.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
